ABOS - Company ID 0001576885
The table below shows Acumen Pharmaceuticals, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $53.08M | $59.44M | $51.80M | $46.83M | $36.81M | $30.16M |
| Short-term investments | $25.53M | $50.75M | $76.60M | $79.78M | $106.56M | $118.99M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $85.13M |
| $115.51M |
| $133.09M |
| $132.15M |
| $148.40M |
| $154.95M |
| Property, plant & equipment | $68.00K | $80.00K | $91.00K | $115.00K | $130.00K | $137.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $85.56M | $116.01M | $133.63M | $142.22M | $171.90M | $204.48M |
| Accounts payable | $6.06M | $13.38M | $1.66M | $682.00K | $2.10M | $1.06M |
| Total current liabilities | $45.09M | $46.85M | $29.23M | $21.96M | $24.86M | $19.32M |
| Long-term debt | $5.87M | $11.90M | $16.92M | $27.05M | $29.88M | $29.53M |
| Total liabilities | $50.95M | $58.74M | $46.15M | $49.05M | $54.82M | $48.96M |
| Retained earnings | -$525.29M | -$499.92M | -$467.20M | -$421.32M | -$394.87M | -$353.92M |
| Total equity | $34.61M | $57.26M | $87.48M | $93.17M | $117.08M | $155.52M |